MedTrace Logo

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

NCT02025413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-12-20

No results posted yet for this study

Summary

The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based).

The primary objective of each comparative cohort (second stage, prostate cancer) is to compare the non-detection rate of circulating tumor cells between the standard and novel methods.

Conditions

  • Metastatic Progressive Castration-resistant Prostate Cancer
  • Metastatic Progressive Breast Cancer

Interventions

DEVICE

Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)

Sponsors & Collaborators

  • Prostate Cancer Foundation

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • Janssen Diagnostics, LLC

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Andrew J Armstrong, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02025413 on ClinicalTrials.gov